graph Evidence gap map comparisons
pembrolizumab based treatment
pembrolizumab plus SoC
mML - L2 - BRAF mutant 1   
Comparator:  vs placebo plus SoC; 
Risk of bias:  low;   some concerns;   high;  NA;